Betta Pharmaceuticals Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
1,700
- Stock Symbol
-
300558
- Investments
-
34
- Share Price
-
$6.90
- (As of Thursday Closing)
Betta Pharmaceuticals General Information
Description
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
Contact Information
Website
www.bettapharma.comCorporate Office
- Number 355 Xingzhong Road, Economic and Technological Development Zone
- Linping District
- Hangzhou, Zhejiang 311100
- China
Corporate Office
- Number 355 Xingzhong Road, Economic and Technological Development Zone
- Linping District
- Hangzhou, Zhejiang 311100
- China
Betta Pharmaceuticals Stock Performance
As of 12-Nov-2026, Betta Pharmaceuticals’s stock price is $6.90. Its current market cap is $2.92B with 423M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.90 | $6.99 | $5.71 - $11.51 | $2.92B | 423M | 12.8M | $0.09 |
Betta Pharmaceuticals Financials Summary
As of 30-Sep-2026, Betta Pharmaceuticals has a trailing 12-month revenue of $552M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 3,484,348 | 3,089,469 | 3,310,968 | 3,289,129 |
| Revenue | 551,639 | 501,902 | 403,033 | 347,171 |
| EBITDA | 68,605 | 144,197 | 112,165 | 94,741 |
| Net Income | 38,687 | 42,458 | 56,104 | 49,193 |
| Total Assets | 1,529,188 | 1,510,090 | 1,279,664 | 1,290,369 |
| Total Debt | 359,533 | 343,366 | 318,763 | 342,847 |
Betta Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Betta Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Betta Pharmaceuticals Patents
Betta Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026184653-A1 | Treatment of subjects having lung cancer with an actionable genetic alteration using a bispecific antibody that binds egfr and cmet | Pending | 06-Mar-2025 | ||
| WO-2026149410-A1 | Degrader targeting pan-kras protein and use thereof | Pending | 07-Jan-2025 | ||
| WO-2026130279-A2 | Treatment of previously treated subjects having colorectal cancer using an anti-egfr rechallenge treatment with a bispecific antibody that binds egfr and cmet | Pending | 16-Dec-2024 | ||
| WO-2026130279-A3 | Treatment of previously treated subjects having colorectal cancer using an anti-egfr rechallenge treatment with a bispecific antibody that binds egfr and cmet | Pending | 16-Dec-2024 | ||
| WO-2025180442-A1 | Hdac inhibitor and use thereof in medicine | Pending | 01-Mar-2024 |
Betta Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Betta Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Betta Pharmaceuticals Investments & Acquisitions (34)
Betta Pharmaceuticals’s most recent deal was a Early Stage VC with Tuosheng Pharma for . The deal was made on 04-Feb-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tuosheng Pharma | 04-Feb-2026 | Early Stage VC | Biotechnology | ||
| Zhixing Pharmaceutical | 16-Dec-2025 | Secondary Transaction - Private | Drug Delivery | ||
| Reprogenix | 01-Nov-2024 | Later Stage VC | Drug Discovery | ||
| Thederma | 23-Oct-2024 | Early Stage VC | Drug Discovery | ||
| Kai Medtech | 24-May-2024 | Later Stage VC | Surgical Devices |
Betta Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.4 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Betta Pharmaceuticals Exits (7)
Betta Pharmaceuticals’s most recent exit was on 11-Apr-2023 from SynRx Therapeutics. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| SynRx Therapeutics | 11-Apr-2023 | Completed |
|
||
| Healthgen Biotech | 30-Mar-2022 | Completed |
|
||
| Clover Biopharmaceuticals | 20-May-2020 | Completed |
|
||
| Righton (Diagnostic Equipment) | 17-Sep-2018 | Completed |
|
||
| Kintor | 13-Feb-2018 | Later Stage VC | Completed |
|
Betta Pharmaceuticals Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Betta Pharmaceutical Biotechnology Fund | Hangzhou, China |
Betta Pharmaceuticals FAQs
-
When was Betta Pharmaceuticals founded?
Betta Pharmaceuticals was founded in 2003.
-
Where is Betta Pharmaceuticals headquartered?
Betta Pharmaceuticals is headquartered in Hangzhou, China.
-
What is the size of Betta Pharmaceuticals?
Betta Pharmaceuticals has 1,700 total employees.
-
What industry is Betta Pharmaceuticals in?
Betta Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Betta Pharmaceuticals a private or public company?
Betta Pharmaceuticals is a Public company.
-
What is Betta Pharmaceuticals’s stock symbol?
The ticker symbol for Betta Pharmaceuticals is 300558.
-
What is the current stock price of Betta Pharmaceuticals?
As of 12-Nov-2026 the stock price of Betta Pharmaceuticals is $6.90.
-
What is the current market cap of Betta Pharmaceuticals?
The current market capitalization of Betta Pharmaceuticals is $2.92B.
-
What is Betta Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Betta Pharmaceuticals is $552M.
-
What is Betta Pharmaceuticals’s annual earnings per share (EPS)?
Betta Pharmaceuticals’s EPS for 12 months was $0.09.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
